Brought to you by 
J&J buying Scios for $2.69bn cash
Feb 2003
Executive Summary
Johnson & Johnson has agreed to acquire Scios Inc. (public biotech; cardiovascular and autoimmune therapeutics) for $2.69bn (or $2.4bn, net of Scios's cash). Scios stockowners will receive $45 for each common share they hold, a 35% premium to the market average in the period before the negotiations were first rumored.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J buying Scios for $2.69bn cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice